Arginine, citrulline, and nitric oxide metabolism in end-stage renal disease patients
J. Clin. Invest. 105:9 doi:10.1172/JCI7199
[Go to this article.]
Options: View larger image (or click on image)
Medium
Figure 3

Illustration of the tracers used on days 1 and 3, and their metabolic fates. (a) Day 1: [1-13C]leucine (I) is converted to [1-13C]α-ketoisocaproate (II), which liberates 13CO2 (III) during its oxidative decarboxylation. L[guanidino-15N2]arginine (IV) liberates 15NO (V) and L-[15N-ureido]citrulline (VI) through the activity of NO synthase. (b) Day 3: L-[13C]ureido[5,5,H2]citrulline (VII) is converted to L-[13C-guanidino, 5,5,2H2] argenine (VIII), which is used as a measure of de novo arginine synthesis. L-[5-13C]arginine (IX) is converted to L-[5-13C]ornithine (X), which is then converted to L-[5-13C]glutamic acid (XI). The latter, via transamination, is then converted to [5-13C]α-ketoglutarate (XII), which upon decarboxylation by α-ketoglutarate dehydrogenase yields [13C]succinyl CoA (not shown). This releases its 13C as 13CO2 (III) during subsequent revolutions of the citric acid cycle.